NICE has published draft diagnostics guidance recommending the MiniMed Paradigm Veo System (Medtronic) for monitoring blood glucose levels in some people with type 1 diabetes.
The draft guidance recommends the system as an option for people who experience frequent episodes of disabling low blood glucose (hypoglycaemia) despite optimal management with insulin pump therapy.
The MiniMed Paradigm Veo system consists of a glucose sensor placed under the skin that continuously measures glucose levels, an insulin pump, and a transmitter which sends glucose level readings wirelessly from the sensor to the pump. The system alerts the user if glucose levels become too high or low, if levels are rapidly changing, or if the system predicts levels will be too high or too low in the near future. The automated low glucose suspend function of the system operates independently of user action and stops insulin delivery for two hours if the user fails to respond to the alert.
